Resource Center

Hard-earned insights that help drug manufacturers achieve their growth, compliance, and profitability objectives

Key Terms in Pharmaceutical Government Pricing

Key Terms in Pharmaceutical Government Pricing

Key Terms in Pharmaceutical Government PricingPharmaceutical pricing can be a challenge to understand and a difficult landscape to navigate. There are multiple prices set for each individual National Drug Code (NDC) – some publicly available and some not. WAC, ASP,...

Part I Unwinding Medicaid Continuous Enrollment

Part I Unwinding Medicaid Continuous Enrollment

Part I – Unwinding Medicaid Continuous Enrollment May 2022After a slight decline from 2017 to 2019, Medicaid enrollment rose sharply throughout the pandemic. Historically, Medicaid enrollment tracks with unemployment rates. When rates rise, enrollment increases....

Update 2023 Best Price Accumulator Adjustment Program Ruling

Update 2023 Best Price Accumulator Adjustment Program Ruling

Update – 2023 Best Price & Accumulator Adjustment Program Ruling2023 was shaping up to be a year of challenging decisions for manufacturers and restricted access to critical pharmaceuticals for patients. The 2023 implementation of the proposed CMS Medicaid Best...

PHS/340B Audit Survival Guide

PHS/340B Audit Survival Guide

PHS/340B Audit Survival GuideEven the most disciplined and compliant companies dread receiving a letter or an email informing them of an impending audit. Nobody likes being put under the microscope. It doesn’t take a great deal of imagination to know what it feels...

Letting Some Air Out of the AMP Inflation Penalty

Letting Some Air Out of the AMP Inflation Penalty

Letting some air out of the AMP inflation penalty.As of late, we have all been bombarded by headlines lamenting or explaining the recent high inflation rates as we consume our daily news. The default reaction to rising inflation is typically in relation to rising...